Susquehanna International Group
RNTX

Susquehanna International Group’s Rein Therapeutics RNTX Stock Holding History

Susquehanna International Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,995
Closed -$68.4K – 14416
2025
Q4 		$68.4K Buy
58,995
+28,135
+91% +$38.8K ﹤0.01% 11637
2025
Q3 		$35.3K Buy
+30,860
New +$39.2K ﹤0.01% 11949
2023
Q4 		– Sell
-20,155
Closed -$30.4K – 13462
2023
Q3 		$30.4K Buy
+20,155
New +$34.2K ﹤0.01% 11480
2022
Q4 		– Sell
-2,521
Closed -$10K – 13916
2022
Q3 		$10K Buy
+2,521
New +$10.6K ﹤0.01% 12782
2022
Q1 		– Sell
-503
Closed -$6K – 14148
2021
Q4 		$6K Buy
+503
New +$7.78K ﹤0.01% 12979

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Susquehanna International Group's RNTX Position: Q1 2026 in Review

Susquehanna International Group sold out of Rein Therapeutics (RNTX) in Q1 2026, closing a stake of 58,995 shares — an estimated $68.4K sold.

Susquehanna International Group first reported a position in RNTX in Q4 2021 and held it in 5 quarters. The position peaked at $68.4K in Q4 2025. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Susquehanna International Group reported no remaining Rein Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 58,995 Rein Therapeutics shares in Q1 2026, an estimated $68.4K.
  • Susquehanna International Group first reported a position in Rein Therapeutics in Q4 2021 and held it in 5 quarters.
  • Susquehanna International Group's Rein Therapeutics position peaked at $68.4K in Q4 2025.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.